@Article{ecn.2015.0370,
AUTHOR = {Ozen Oz Gul, Soner Cander, Bulent Gul, Ebru Açıkgoz, Emre Sarandol, Canan Ersoy},
TITLE = {Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome},
JOURNAL = {European Cytokine Network},
VOLUME = {26},
YEAR = {2015},
NUMBER = {4},
PAGES = {73--78},
URL = {http://www.techscience.com/ECN/v26n4/65545},
ISSN = {1952-4005},
ABSTRACT = {This study was designed to evaluate insulin resistance and plasma levels of visfatin and resistin in
obese and non-obese patients with polycystic ovary syndrome (PCOS).A total of 37 premenopausal PCOS patients
with (n = 18, mean (SD) age: 27.5 (5.7 years) or without obesity (n = 19, mean (SD) age: 23.7 (3.1) years) and healthy
volunteers (n = 18, mean (SD) age:29.8 (4.1) years) were included in this study. Data on clinical characteristics,
glycemic parameters and lipid parameters were recorded for each subject as were plasma visfatin and resistin
levels. Mean (SD) HOMA-IR values were significantly higher in obese PCOS patients (3.4 (1.7)) compared with
non-obese PCOS patients (2.0 (1.2), p<0.01) and controls (1.6 (0.8), p<0.01). No significant difference was noted
between study groups in terms of plasma resistin (ng/mL) or visfatin (ng/mL) levels. There was no correlation
between serum plasma visfatin (r = 0.127, p = 0.407) and resistin (r = -0.096, p = 0.544) levels and HOMA-IR.
In conclusion, our findings revealed increased likelihood of metabolic and dyslipidemic manifestations in obese
compared to non-obese PCOS patients, while no significant difference was noted in visfatin and resistin levels
among PCOS patients in terms of co-morbid obesity and in comparison to controls.},
DOI = {10.1684/ecn.2015.0370}
}